{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T08:40:40Z","timestamp":1771058440151,"version":"3.50.1"},"reference-count":68,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":2045,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:p>As Parkinson's disease progresses, fluctuations between akinesia, or hypomobility (\u201coff\u201d times), and mobility (\u201con\u201d times) increase in frequency despite optimized pharmacotherapy. Motor fluctuations include predictable shortening of therapeutic effects, nocturnal or early morning akinesia, random hypomobility, and delayed mobility (variable responses to individual doses of drugs). Current oral antiparkinson drugs are inadequate for rapid and consistent relief of symptoms during hypomobility. Apomorphine, an injectable dopamine agonist recently introduced in the United States, is indicated for the management of hypomobility associated with advanced Parkinson's disease. Subcutaneous apomorphine is effective for rapid and consistent rescue from hypomobility, with a magnitude of motor improvement similar to that of levodopa. The effect begins within 20 minutes after dosing and lasts approximately 100 minutes. Therapeutic rescue doses are 2\u20136 mg, and patients typically require approximately three rescue doses\/day. Apomorphine is associated with a clinically significant potential to cause nausea and orthostatic hypotension. These potential effects can be managed with antiemetic prophylaxis and appropriate determination of the therapeutic rescue dose.<\/jats:p>","DOI":"10.1592\/phco.26.6.840","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T13:14:16Z","timestamp":1148303656000},"page":"840-852","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Update on Apomorphine for the Rapid Treatment of Hypomobility (\u201cOff\u201d) Episodes in Parkinson's Disease"],"prefix":"10.1002","volume":"26","author":[{"given":"Crystal D.","family":"Obering","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Swope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"An essay on the shaking palsy","author":"Parkinson J.","year":"1817"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16305-8"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00827-0"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410400417"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10483"},{"key":"e_1_2_1_7_2","volume-title":"Brunner and Suddarth's textbook of medical\u2010surgical nursing","author":"Smeltzer S.C.","year":"2000"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.2_Suppl_2.S25"},{"issue":"7","key":"e_1_2_1_9_2","first-page":"S6","article-title":"Clinical aspects of motor fluctuations in Parkinson's disease","volume":"44","author":"Poewe W.","year":"1994","journal-title":"Neurology"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2004.06.007"},{"issue":"4","key":"e_1_2_1_11_2","first-page":"S27","article-title":"Rapid treatment of \u201cwearing off\u201d in Parkinson's disease","volume":"62","author":"Swope D.M.","year":"2004","journal-title":"Neurology"},{"issue":"12","key":"e_1_2_1_12_2","first-page":"S2","article-title":"Complications and limitations of drug therapy for Parkinson's disease","volume":"55","author":"Jankovic J.","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000118883","article-title":"Management of motor fluctuations in Parkinson's disease","volume":"36","author":"Koller W.C.","year":"1996","journal-title":"Eur Neurol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.3_Suppl_3.S1"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_5.S1"},{"key":"e_1_2_1_16_2","first-page":"351","article-title":"Concentration\u2010effect relationship of levodopa\u2010benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease","volume":"22","author":"Contin M.","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199710050-00002"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6_Suppl_6.S27"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420511"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199619010-00005"},{"key":"e_1_2_1_21_2","first-page":"259","article-title":"The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double\u2010blind cross\u2010over study versus placebo","volume":"9","author":"Stocchi F.","year":"1994","journal-title":"Funct Neurol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00868995"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007583422634"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1081\/DDC-120001486"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000116649"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb05555.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(91)90143-Y"},{"issue":"11","key":"e_1_2_1_28_2","first-page":"38","article-title":"A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50\/200) and standard Sinemet (25\/100)","volume":"39","author":"Cedarbaum J.M.","year":"1989","journal-title":"Neurology"},{"issue":"11","key":"e_1_2_1_29_2","first-page":"45","article-title":"Controlled\u2010release carbidopa\/levodopa (Sinemet 50\/200 CR4): clinical and pharmacokinetic studies","volume":"39","author":"LeWitt P.A.","year":"1989","journal-title":"Neurology"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241040-00003"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.7.1287"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059060-00004"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.5.913"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5_Suppl_5.S31"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.5.589"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090416"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6.1493"},{"key":"e_1_2_1_38_2","first-page":"351","article-title":"Concentration\u2010effect relationship of levodopa\u2010benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease","volume":"22","author":"Contin M.","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_39_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3928\/0191-3913-20001101-06","article-title":"Development of two stable oral suspensions of levodopa\u2010carbidopa for children with amblyopia","volume":"37","author":"Nahata M.C.","year":"2000","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.5.1036"},{"issue":"4","key":"e_1_2_1_41_2","first-page":"S83","article-title":"DA agonist\u2013non\u2010ergot derivatives: apomorphine","volume":"17","author":"Goetz C.G.","year":"2002","journal-title":"Mov Disord"},{"key":"e_1_2_1_42_2","first-page":"159","article-title":"Pharmacokinetics, enantiomer interconversion and metabolism of R\u2010apomorphine in patients with idiopathic Parkinson's disease","volume":"21","author":"Geest R.","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937030-00004"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0753-3322(96)82620-5"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91193-2"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.53.11.1004"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.52.4.544"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91755-2"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92487-2"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.53.2.96"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.4.358"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199106000-00003"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080208"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.56.1.101"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199304000-00003"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.6.681"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.65.5.709"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.9.1385"},{"key":"e_1_2_1_59_2","volume-title":"NDA 21\u2013264. Apokyn (apomorphine hydrochloride injection) 10 mg\/mL","author":"Mylan Bertek Pharmaceuticals Inc.","year":"2004"},{"issue":"1","key":"e_1_2_1_60_2","first-page":"A81","article-title":"Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of off episodes in patients with Parkinson's disease [abstr]","volume":"60","author":"Sherry J.H.","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"e_1_2_1_61_2","first-page":"S217","article-title":"Decrease in UPDRS motor scores following intermittent subcutaneous apomorphine for 6 months in patients with advanced Parkinson's disease [abstr]","volume":"19","author":"Trosch R for the APO303 Investigators","year":"2004","journal-title":"Mov Disord"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197001012820107"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199704000-00008"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/107.2.487"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/0303-8467(93)90128-4"},{"key":"e_1_2_1_66_2","first-page":"S20","article-title":"Use of trimethobenzamide for the control of nausea in advanced Parkinson's disease patients treated with subcutaneous apomorphine [abstr]","volume":"19","author":"Dewey RB Jr for the APO\u2010401 Investigators","year":"2004","journal-title":"Mov Disord"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119100-00004"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.11.2297"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130108"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.6.840","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.6.840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:32:29Z","timestamp":1761064349000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.6.840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1592\/phco.26.6.840"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.6.840","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}